Notably, targeting CEACAM1 for selective depletion of Tregs can effectively remove highly suppressive Tregs from the tumor microenvironment, thereby improving the efficacy of immune therapies and providing a novel immune therapeutic strategy. This evidence concerns the gene CEACAM1 and neoplasm.